Carmat SA (EPA: ALCAR)

Market Cap	41.00M
Revenue (ttm)	6.93M
Net Income (ttm)	-53.35M
Shares Out	42.39M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	159,782
Open	1.000
Previous Close	0.999
Day's Range	0.967 - 1.008
52-Week Range	0.960 - 7.720
Beta	1.49
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 23, 2024

About Carmat

Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 182
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCAR

Financial Performance

In 2023, Carmat's revenue was 3.84 million, an increase of 704.40% compared to the previous year's 477,000. Losses were -53.87 million, 0.35% more than in 2022.